GlaxoSmithKline plc (GSK.L)
| Previous close | 1,300.60 |
| Open | 1,317.40 |
| Bid | 1,300.00 x 0 |
| Ask | 1,320.00 x 0 |
| Day's range | 1,304.20 - 1,322.40 |
| 52-week range | 1,190.80 - 1,748.55 |
| Volume | 6,592,342 |
| Avg. volume | 11,056,900 |
| Market cap | 66.394B |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 11.57 |
| EPS (TTM) | 114.10 |
| Earnings date | 28 Apr 2021 |
| Forward dividend & yield | 0.80 (6.06%) |
| Ex-dividend date | 18 Feb 2021 |
| 1y target est | 1,644.50 |
- Motley Fool
How Important Is Novavax's COVID Vaccine Manufacturing Deal With GlaxoSmithKline?
GlaxoSmithKline (NYSE: GSK) has teamed up with several other companies to develop COVID-19 vaccine candidates. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how important this manufacturing deal with GlaxoSmithKline is for Novavax. Keith Speights: Novavax -- the ticker there is NVAX -- announced this week that it's teamed up with GlaxoSmithKline -- ticker there is GSK -- to support the manufacturing of its COVID vaccine in the United Kingdom.
- Motley Fool
Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?
GlaxoSmithKline (NYSE: GSK), Vir Biotechnology (NASDAQ: VIR), and Eli Lilly (NYSE: LLY) recently reported positive results from a phase 2 study evaluating a combination of Lilly's bamlanivimab with Vir's and Glaxo's VIR-7831 in treating COVID-19. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli examine those results and discuss which of the three stocks is likely to be the biggest winner going forward.
- Motley Fool
3 Stocks That Could Suffer if Biden Gives In to This Pressure
A proposal currently before the World Trade Organization would waive patent rights on COVID-19 vaccines and treatments in an effort to help low-income nations. Several top Democrats appear to support the move, although the Biden administration has yet to state a position publicly. Despite the push, the president may be hesitant to override patents for pharmaceuticals.
